For more advanced stages, with high blood tumor burden, it is preferable to start with debulking agents and then use ECP; in this scenario anti-CCR4 mogamulizumab can induce a high response rate, particularly in the blood, thus reducing the number of atypical cells. Here, CCR4 is linked to neoplasm.